Rosacea is a chronic inflammatory skin disorder commonly characterized by centrofacial erythema, papules, pustules, vascular instability, and ocular involvement. Although extensively studied in lighter skin tones, significant disparities remain in the diagnosis, detection, and treatment of rosacea in individuals with skin of color. This review examines current literature regarding rosacea in melanin-rich skin with emphasis on prevalence, biomarkers, pathophysiology, diagnostic challenges, Demodex folliculorum involvement, and treatment approaches. Current diagnostic standards rely heavily on visible erythema and telangiectasia, which are often less apparent in darker skin tones, contributing to underdiagnosis and delayed treatment. Research also suggests differences in inflammatory biomarkers, post-inflammatory hyperpigmentation, and vascular responses in skin of color. Treatment methods including topical therapies, lifestyle modifications, and laser-based thermal therapies are reviewed alongside their limitations and risks in melanated skin. Emerging diagnostic technologies, such as computer-aided imaging systems and biomarker-based approaches, demonstrate potential for improving diagnostic accuracy across diverse populations. Overall, this review highlights the need for more inclusive research, improved clinical education, and culturally competent diagnostic criteria to better address rosacea in underrepresented populations and reduce disparities in dermatologic care.
SNU-407 colorectal cancer cells were treated with 300nM MRTX1133 for 0, 24, 48, and 72 hours before lysis and loading onto 7.5% SDS-PAGE gels. Gels were transferred to nitrocellulose membranes and cut at the 95kDa and just below the 52 kDa molecular weight (MW) markers. Membranes were then probed for proteins that fell within the MW and evaluated for change in comparison to the 0h control.
SNU-407 cells were treated with a combination of varying concentrations of MRTX1133 with varying concentrations of either afatinib, sapitinib, or pelitinib for 72 hours. Absorbances were normalized to DMSO control for % viability. The attached files were compiled in data format from n=2 data sets (6 data points total for each combination) and uploaded to SynergyFinder+ with % viability chosen as response.
LS513 cells were treated with a combination of varying concentrations of MRTX1133 with varying concentrations of either afatinib, sapitinib, or pelitinib for 72 hours. Absorbances were normalized to DMSO control for % viability. The attached files were compiled in data format from n=2 data sets (6 data points total for each combination) and uploaded to SynergyFinder+ with % viability chosen as response.